"Ossan Healthcare Osan Healthcare Over-the-Counter Stocks, Medical Device Manufacturers, and Exchange Listing Preliminary Review Approval!!

“Ossan Healthcare Osan Healthcare Over-the-Counter Stocks, Medical Device Manufacturers, and Exchange Listing Preliminary Review Approval!!

Today, I’m going to talk about Five-Phase Healthcare.Five-phase Healthcare, which has been focusing on developing blood diagnostic biosensors, aims to make “Technology for Everyone” a world where all diseases can be easily measured with the aim of home appliances. It exports the world’s best technologies such as blood glucose measurement biosensors, HbA1c measurement biosensors, and cholesterol measurement biosensors to more than 110 countries around the world, and aims to become the best company in diagnostic bio.

According to the investment banking (IB) industry, OSANG Healthcare received approval from the Korea Exchange for a preliminary review of KOSDAQ listing the previous day. The listed company is called NH Investment & Securities.

This is Osang Healthcare’s second listing challenge. In 2021, he tried to be listed on the KOSDAQ as a special case for non-realization of profits (Tesla requirements), but eventually failed to cross the exchange threshold, and his past delisting history, embezzlement of management, and performance stability acted as obstacles.

Osan Group acquired KOSDAQ-listed company Infopia, the predecessor of Osan Healthcare, in 2016. At that time, Infopia was delisted that year after allegations of embezzlement and breach of trust by executives were raised.After that, the company changed its name to Osang Healthcare and focused on in vitro diagnostics. As its performance rebounded due to positive factors from COVID-19, it challenged to be listed on the KOSDAQ. However, the exchange judged at the time that it was unclear whether performance stability would be maintained even after the COVID-19 pandemic.

During the preliminary listing review process, it was judged that much of the problems raised at the time were resolved. Four committees were formed around outside directors to strengthen the internal control system and set up a separate audit committee.

Even after the COVID-19 pandemic ended, OSANG Healthcare’s performance has continued to increase. Until the third quarter of this year, sales and operating profit were 336.9 billion won separately. Sales and operating profit rose 56% and 45% year-on-year, and this year’s operating profit surplus was achieved following last year, so this time it is seeking to list the general public, not a special case of unfulfilled profits.

The fact that sales of COVID-19 diagnostic kits still account for more than 80% is considered a limit. Osan Healthcare announced its plan to diversify into businesses other than diagnostic devices in the future and reduce concerns about performance stability.

Osan Healthcare participated in WiseMedi’s paid-in capital increase, a subsidiary of Yuhan Corporation, in July and became the second largest shareholder with a 12.7% stake. It is a stepping stone to expand our business by exporting specialized medicines. Osang Healthcare is in charge of overseas sales of nutritional fluids made by WiseMedi.

Osang Healthcare is also preparing a digital healthcare platform as a new business. It is a service that can prevent diseases and maintain health without going to the hospital. Osang Healthcare is developing a platform that integrates healthcare devices based on its existing in vitro diagnostic devices.

The largest shareholder is Osan, the holding company of Osan Group. It is said that it holds a 38.9% stake in Osan Healthcare. The stake, including related parties such as Osan Zayer (16.3% stake) and Osan Group Chairman Lee Dong-hyun (5.5%) is 62.8%.

Osang Healthcare is promoting the excellence of Korean biotechnology to the world based on its own technology. From the United States and India to North and Central America, South America, Europe, Asia, Africa and Oceania, you can experience five-phase healthcare products all over the world. However, they are not satisfied with this and are constantly striving to become a healthcare company around the world.

Oseong Healthcare is drawing keen attention as it is a company that continues to conduct research in various fields such as biochemical diagnosis, immune diagnosis, molecular diagnosis, and mobile healthcare. We can say that we are looking forward to the future of this company!Oseong Healthcare is drawing keen attention as it is a company that continues to conduct research in various fields such as biochemical diagnosis, immune diagnosis, molecular diagnosis, and mobile healthcare. We can say that we are looking forward to the future of this company!§ Five-phase health care §Phone: 010-4668-1648https://www.youtube.com/shorts/jaF7lOSXXuE